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BACKGROUND
Atherosclerosis leads to cardiovascular diseases (CVD), a major cause of morbidity and mortality 1, 2 . The endothelium plays a role in atherogenesis, and endothelial dysfunction is considered to be involved in the onset of CVD and its progression 2 . Endothelial dysfunction results in reduced nitric oxide and prostacyclin bioavailability, vasoconstriction, oxidative stress, inflammation, and platelet activation 3, 4 .
Among molecules that may modulate endothelial function, endothelin-1 (ET-1) is a peptide, which is primarily produced by vascular endothelial cells 5 . ET-1 was first identified as a vasoconstrictor 6 . The synthesis of ET-1 starts from precursor peptides; endothelin-converting enzyme converts pro-endothelin to ET-1 7 . ET-1 is multifunctional, and promotes inflammation and cell proliferation within arterial vessel walls 5 . The synthesis of ET-1 is mediated by various factors, including oxidized low-density lipoprotein (LDL), platelet activation, and hypoxia [8] [9] [10] .
Conversely, ET-1 may also induce LDL oxidation and platelet activation 11 . Thus, overproduction of ET-1 may be associated with increased risk for CVD 5 . The control of ET-1 expression might provide benefits against the development of atherosclerosis and CVD events.
Consistent with this is the observation that antagonism of the ET-1 system can modify atherogenesis 12 .
Many clinical trials have reported the beneficial effects of statins in CVD prevention [13] [14] [15] [16] .
Recently, attention has been paid to the pleiotropic actions of statins beyond simple cholesterollowering [17] [18] [19] . In experimental studies, statins can inhibit ET-1 production 20 ; however, findings concerning changes in ET-1 concentrations following statin therapy have been inconsistent.
Therefore, in the present meta-analysis we evaluated the impact of statin therapy on circulating ET-1 concentrations.
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METHODS
Search Strategy
This study was designed according to the guidelines of the 2009 preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement 21 . Our search included SCOPUS (http://www.scopus.com), Medline (http://www.ncbi.nlm.nih.gov/pubmed), Web of Science (http://apps.webofknowledge.com), and Cochrane Library (www.thecochranelibrary.com/)
databases. It was limited to randomized controlled trials (RCTs) carried out from January 1, 1970 to September 30, 2014 , investigating the potential effects of statin therapy on ET-1 concentrations. The databases were searched using the following search terms in titles and abstracts (also in combination with MESH terms): (rosuvastatin or pravastatin or fluvastatin or simvastatin or atorvastatin or pitavastatin or lovastatin or cerivastatin or "statin therapy" or statins) and (endothelin-1 or endothelin or ET-1). The wild-card term ''*'' was used to increase the sensitivity of the search strategy. No language restriction was used in the literature search.
The search was limited to studies in human. Two reviewers (CS and AS) evaluated each article separately. Disagreements were resolved by discussion with a third party (MB).
Study Selection
Original studies were included if they met the following inclusion criteria: (i) a randomized controlled trial (RCT) in either parallel or cross-over design, (ii) investigating the impact of statin therapy on plasma/serum levels of ET-1, (iii) treatment duration of at least two weeks, and, (iv) presentation of sufficient information on ET-1 concentrations at baseline and at the end of study in both statin and control groups or providing the net changes in each group.
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5 Exclusion criteria were: (i) non-clinical studies, (ii) uncontrolled trials, (iii) lack of sufficient information on baseline or follow-up ET-1 levels, (iv) inability to obtain adequate details of study methodology or results from the article or the investigators, and, (v) the study was ongoing. Exclusion of an article for the latter reason was carried out if no feedback was received after contacting the author(s).
Data extraction
Eligible studies were reviewed and the following data were abstracted: 1) first author's name, 2) year of publication, 3) study location, 4) number of participants in the statin and control groups, 5) age, gender and body mass index (BMI) of study participants, 6) baseline levels of total cholesterol, LDL cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, high-sensitivity C-reactive protein (hsCRP) and glucose, 7) systolic and diastolic blood pressure, and, 8) data regarding baseline and follow-up concentrations of ET-1. In case the values were only presented as graphs, the GetData Graph Digitizer 2.24 (http://getdata-graphdigitizer.com/) software was used to digitize and extract the data.
Quality assessment
The quality of included studies was assessed using the Jadad scale. This scale encompasses randomization (0-2 points), blinding (0-2 points), and dropouts and withdrawals (0-1 point). The overall score of a study according to this scale ranges between 0-5, with higher scores indicative of a better quality 22 . Studies with Jadad scores of ≤2 and ≥3 were considered as low-and highquality, respectively 23 .
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Quantitative Data Synthesis
Meta-analysis was conducted using Review Manager, version 5.2 (Cochrane Collaboration),
and Comprehensive Meta-Analysis (CMA) V2 software (Biostat, NJ) 24 . Standard deviations (SDs) of the mean difference were calculated using the following formula: SD = square root [(SD pre-treatment ) 2 + (SD post-treatment ) 2 -(2R × SD pre-treatment × SD post-treatment )], assuming a correlation coefficient (R) = 0.5. In case of reporting SEM, SD was estimated using the following formula:
where n is the number of subjects.
Net changes in measurements (change scores) were calculated for parallel and cross-over trials, as follows: (measure at end of follow-up in the treatment group − measure at baseline in the treatment group) − (measure at end of follow-up in the control group − measure at baseline in the control group). A random-effects model (using DerSimonian-Laird method) and the generic inverse variance method were used to compensate for the heterogeneity of studies in terms of statin type, statin dose, study design, treatment duration, and the characteristics of populations being studied 25 . Effect sizes were expressed as weighed mean difference (WMD) and 95% confidence interval (CI). Post-hoc subgroup analyses were carried out to explore the impact of dose (<40 mg/day vs >40 mg/day), duration (<12 weeks vs >12 weeks), and type (lipophilic vs hydrophilic) of statin therapy on plasma ET-1 concentrations. In order to evaluate the influence of each study on the overall effect size, sensitivity analysis was conducted using the one-study remove (leave-one-out) approach 26 . The power of analysis to detect statistically significant difference between statin and control groups was performed using the PS software 27 .
In the absence of trials making head-to-head comparison of hydrophilic versus lipophilic statins, the effect of these two types of statins on plasma ET-1 levels were compared using adjusted indirect comparison according to the method proposed by Song et al. 28 and Bucher et
al. 29 . In this method, treatment effects estimated for each type of statins in the random-effects model could be compared indirectly through common controls.
Meta-regression
Random-effects meta-regression was performed using unrestricted maximum likelihood method to evaluate the association between calculated WMD in plasma ET-1 concentrations with duration and dose of treatment with statins, as well as age, gender and changes in plasma LDL-C concentrations as potential moderators of treatment response.
Publication bias
Potential publication bias was explored using visual inspection of Begg's funnel plot asymmetry, and Begg's rank correlation and Egger's weighted regression tests. Duval and Tweedie "trim and fill" and "fail-safe N" methods were used to adjust the analysis for the effects of publication bias 30 .
Heterogeneity Analysis
Heterogeneity analysis was performed using the Cochrane's Q test and I 2 index. Another attempt to explore heterogeneity was made via the Galbraith plot, a scatter plot of WMD divided by its standard error (Z-statistic) against the reciprocal of the standard error in the included studies.
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RESULTS
The initial screening for potential relevance removed the articles in whose titles and/or abstracts were obviously irrelevant. Among the 30 full text articles assessed for eligibility, 15 studies were excluded because of: lack of assessment of plasma ET-1 concentrations (n=1), insufficient data on plasma ET-1 levels (n=4), not being an original research study (n=1), not having an appropriate RCT design (n=4), short (<2 weeks) duration of treatment (n=2) and nonEnglish language (n=3) (Figure 1) .
Characteristics of included studies
After final assessment, 15 RCTs 31-45 met the inclusion criteria and were considered for the final meta-analysis. In total, 810 participants were randomized, of whom 421 were allocated to Table 1 . The systematic assessment of bias in the included studies is shown in Supplemental Table 1 .
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Quantitative data synthesis
The meta-analysis of data from 15 RCTs (comprising 16 treatment arms) [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] 
Meta-regression
The meta-regression analysis was conducted to assess the association of changes in plasma 
Publication bias
The funnel plot of the study precision (inverse standard error) by effect size (mean difference) was asymmetric and suggested potential publication bias. This 
Heterogeneity analysis
The meta-analysis indicated a significant heterogeneity based on the calculated 
DISCUSSION
The present meta-analysis suggests that statin therapy reduces plasma ET-1 concentrations.
The efficacy of statins was independent of therapeutic duration or dose. Since there have been no intervention studies specific for the reduction of ET-1 levels in relation to the CVD outcomes, the relevance of the mean level of the reduction (-0.30 pg/mL) on CVD prevention still remains to be determined. Even if so, these findings are of large interest since ET-1 may be a potential therapeutic target for atheroprotection 5 .
The robustness of our combined analysis was verified in sensitivity analysis and it was found that the significance of the pooled estimate is the result of all studies rather than a single ET-1 in the circulation mainly stems from vascular cells 5 , while urinary ET-1 is thought to reflect kidney derived production 50 . It has been suggested that urinary ET-1 reflects overall endogenous production of this protein 51 . Besides plasma ET-1 measurement, 4 studies included in this meta-analysis measured urinary ET-1 levels; they confirmed a significant reduction of urinary ET-1 during statin therapy [36] [37] [38] 41 .
In addition to cholesterol-lowering effects, the so-called pleiotropic effects of statins have been the subject of increasing debate 17, 18 . These effects may be mainly due to LDL-C reduction M A N U S C R I P T This meta-analysis has limitations. The studies included had relatively short follow-up durations (2 weeks -12 months) and most had a small number of participants (32 -82).
A C C E P T E D ACCEPTED MANUSCRIPT
Furthermore, in relation to the study durations, they did not assess long-term CVD outcomes.
The variations in study durations and statin doses may have not been of sufficient diversity
to assess the impact of these factors on the ET-1-lowering effect of statins. Therefore, there is still a need for data from additional trials to identify determinants of ET-1 response to statin therapy, and also the impact of novel LDL-lowering agents 65, 66 on plasma ET-1
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levels. To address inter-study heterogeneity, a conservative random-effects model was applied. In addition, sensitivity analysis confirmed that the pooled estimate is not significantly deviated by a single study.
CONCLUSIONS
In conclusion, the findings of the present meta-analysis suggest that statin therapy significantly reduces plasma ET-1 concentrations, regardless of treatment duration or statin dose. 
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